Cells integrate extracellular signals into appropriate responses through a complex network of biochemical reactions driven by the activity of protein and lipid kinases, among other proteins. In order to understand this complexity, new approaches, both experimental and computational, have recently been developed with the aim to identify regulatory kinases and infer their activation status in the context of their signalling network. Here, we review such approaches with particular focus on those based on phosphoproteomics. Integration of kinase activity measurements inferred from phosphoproteomics data with other 'omics' datasets is starting to be used to identify regulatory nodes in biochemical networks. These methodologies may in the future be used to identify patient-specific targets and thus advance personalised cancer medicine.
Kinases are a group of enzymes that catalyse the transfer of phosphate groups from ATP to acceptor molecules. The focus of this review is on protein and lipid kinases with roles on the regulation of signal transduction, as these enzymes mediate a cell's ability to interpret, adapt and respond to environmental cues. The significance of kinase signalling is underscored by the human genome encoding for over 500 protein kinases [1] representing 1.7% of all coded genes within the genome, thus being one of the largest groups of evolutionarily related proteins. Protein kinases regulate signalling networks through reversible protein phosphorylation of a tyrosine, serine or threonine residue on target proteins substrates [1] and lipid phosphorylation (e.g. through the phosphoinositide system) generates second messengers which in turn activate numerous downstream kinase cascades [2, 3] . In addition, phosphorylation on other amino acids such as histidine is widely recognised in bacteria, fungi and plants [4] and examples are beginning to be described in mammalian systems [5] . Consequently, protein phosphorylation is the most studied protein post-translation modification (PTM) and, in concert with regulators such as by GTPases, second messengers and other forms of PTMs (e.g. ubiquitination, methylation, acetylation, O-GlcNacylation and ADP-ribosylation), phosphorylation regulates the transduction of signals from cell surface receptors to changes in gene expression and cell behaviour [6, 7] . Although signalling pathways are often represented as linear kinase-mediated signalling cascades [8] (Fig. 1A) , it is now clear that such pathways form complex networks of biochemical reactions. Another issue that confounds the field is that the wirings of these networks are cell type specific and evolve during differentiation and ageing, and therefore representation of canonical signalling pathways in diagrams [9] , although useful to conceptualise some of their properties, is not representative of the signalling network in a given cell type under a defined set of conditions [10] [11] [12] (Fig. 1B) .
The need for a quantitative understanding of kinase signalling
The activation of kinase cascades has profound consequences for cell behaviour as these have the potential to regulate many different cell biological processes such as cell survival, migration, metabolism, growth or proliferation, and many disease phenotypes can arise from kinase dysregulation. This is particularly evident in oncogenesis, although kinases have also been implicated in neurodegeneration, metabolic syndrome and autoimmune disease [13] [14] [15] [16] [17] [18] .
Most cancers are caused by the gradual accumulation of mutations in genes with roles in regulating cell cycle progression and prosurvival pathways [19] . Indeed, genes that code for proteins with roles in controlling prosurvival and proliferative cell signalling pathways, which include protein and lipid kinases and their regulators, comprise one of the classes of genes that need to be mutated for cancer to ensue [20] . Specific kinase mutations, such as activating EGFR mutations in lung cancer and BRAF mutations in melanoma, drive disease progression, and accordingly, therapeutically targeting such enzymes can produce partial responses in a large proportion of cases showing the respective mutations [21] [22] [23] . In addition, combination treatment with dabafenib (a B-RAF inhibitor) and trametinib (a MEK inhibitor) improved the overall survival of patients with BRAF mutations [24] . PIK3CA provides another example of an oncogene frequently found to be amplified or mutated in different carcinomas such as ovarian cancer [25] . Fig. 1 . Models of cell signalling (A) Example of a canonical signalling cascade compiled from several literature sources showing a composite (averaged) network derived from studies that used many different tissues and organisms. In this representation, linear distinct pathways transmit signalling to adaptor proteins and kinases, inducing functional outputs (i.e. cell proliferation, transcriptional activity, cell growth, metabolism, etc.). (B) Empirically defined kinase signalling network of MCF7 cells illustrating experimentally identified activity markers specific for this cell line. Figure 1B reproduced from ref. [124] . Kinase pathways are plastic by nature, and network rewiring is known to occur during transformation and as patients become resistant to treatments [30] . Thus, although targeting aberrant kinase activity in oncology remains an attractive therapeutic option, the success of such therapies requires identifying kinase dependencies in cancer cells and biomarkers of sensitivity so that oncologists are able to select the correct inhibitor for each patient [21, 32] . Current approaches to stratify patients for therapy are based on the analysis of genetic mutations, which provide proxies of pathway activation, but it has been argued that more precise companion diagnostic approaches will require the ability to quantify kinase activity more directly [33] .
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Here, we first briefly review current approaches to identify patient-specific regulatory kinases based on the analysis of somatic genetic driver mutations. We then consider alternative methodologies based on functional and biochemical assays, and give particular attention to recently developed approaches based on computational science to analyse phosphoproteomics data and to integrate different omics datasets. The different approaches covered in this review are summarised in Table 1 .
Approaches to identify regulatory kinases
Landscape of genetic mutations that affect kinase signalling Somatic mutations on kinase-coding genes, their substrates and upstream regulators are frequently observed in cancer. Large-scale and systematic gene sequencing studies have identified gain of function mutations on regulatory kinases, such as BRAF, PIK3CA and KIT, among many others [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] , which are commonly found in different tumours and which are known to result in their constitutive activation. These overactive kinase in turn increase the activation of downstream oncogenic pathways thus contributing to oncogenesis [47, 48] . In addition to kinases with well-known roles in the regulation of cell biology, Greenman et al. [49] observed that putative driver mutations often occur on kinases that do not necessarily have well described roles in promoting cell viability and proliferation. Despite these advances, the functional significance of most somatic mutations remains to be elucidated [50, 51] and some mutations that were initially thought to be activating (such as those in PKC isoforms) have been found to be inactivating when these were evaluated experimentally [52] . Other kinases, such as JNK family kinases, which are frequently mutated in cancer [49] , can have both tumour suppressor and tumour-promoting functions depending on context. An extensive review of 'kinasopathies' kinase related germline disorders other than cancer, can be found in Lahiry et al. [22] . An example of hereditary predisposition to child neuroblastoma is given by point mutations in the tyrosine kinase (TKD) domain of the anaplastic lymphoma kinase (ALK) [53] .
Genetic aberrations can also lead to the formation of fusion proteins with oncogenic properties -the classical example being the BCR-ABL TKD in the Philadelphia chromosome that drives chronic myeloid leukaemia (CML) [54] . The ABL TKD is constitutively active when fused with BCR, leading to the formation of the BCR-ABL/GRB2/GAB2/SOS complex that causes constitutive activation of the Ras downstream pathway, thereby activating MAPK pathway proteins [143] and resulting in abnormal cell proliferation [55, 56] . BCR-ABL also activates the PI3K/AKT pathway [54] , which promotes survival by suppressing the activity of the transcription factor FOXO, activation of the antiapoptotic machinery and enhancement of cell proliferation and metabolism by inducing mTOR activation [57] [58] [59] . Other oncogenic gene fusion events include BCR-FGR1, ALK-NMP1 and EML4-ALK [60] [61] [62] .
Collectively the study of these kinase-associated genetic aberrations has helped in the understanding of kinase-regulated pathways.
Expression levels of kinases
Copy number of genes that encode for proteins kinases, such as ribosomal protein S6 kinase 2 (S6K2) [63] or activated CDC42 kinase 1 (TNK2) [64] , and different PKC isoforms [65] ) [67] . Kothari et al. tested the hypothesis that kinases with enhanced expression may be essential for the viability of breast and pancreatic cancer cells; the authors used RNA-Seq transcriptomics data from 482 samples from 25 different cancer/tissue types to analyse their dependency to 468 kinases using RNAi as well as pharmacologic inhibitors as validation tools [21] . ERBB2 and FGFR4 were found to be frequently overexpressed in breast cancer while overexpression of MET, AKT and PLK2 were more frequent in pancreatic cancers. Taken together, a number of studies suggest that assessing the expression levels of kinases may occasionally identify kinase dependencies. However, as the activation of regulatory kinases is rarely associated with their expression levels [68] [69] [70] (see below), kinase gene expression may not always be a reliable indication of how active such kinases may be in cells.
Systematic kinase knockdown studies
As an alternative to measuring gene expression, systematic knockdown studies, by either genetic or pharmaceutical means, have been used to systematically identify regulatory kinases in cancer cells. For example, Grueneberg et al. [71, 72] performed a largescale kinase knock-down screen in cell lines using shRNA libraries, with the aim to identify essential kinases across cancer cells of different tissue of origin. This systematic knockdown approach showed that different cancers and cell types rely on different kinases for survival, thus highlighting the heterogeneity of kinase dependence of cancer cells. Tyner et al. [73] screened a cohort of primary cells obtained from 30 leukaemia patients using RNAi and found that cell viability of malignant cells was reduced by knockdown of TKDs in a third of cases. Later studies used highthroughput systematic RNAi approaches targeting > 600 kinases in cancer to identify kinase genes implicated in chemotherapeutic resistance [74, 75] . These studies concluded that, in many cases, the observed resistance phenotype is caused by the activity of kinases, some of which such as PTK2, MAP2K1, PIK3CA and PRKCB are known to regulate common signalling pathways [73] . The results from systematic functional knockdown efforts are consistent with systematic gene sequencing studies that have identified recurrent mutations in a large number of poorly studied kinases [49] , and highlight the need to identify therapeutic targets in an unbiased manner through screens that measure global signalling. A limitation of these studies, however, is that functional screenings are restricted to the investigation of signalling in preclinical systems and cannot be easily translated to a clinical setting.
Kinase inhibition sensitivity profiling
To rank kinase dependencies in cancer, Yadav et al. developed the drug sensitivity score (DSS) by integrating multiple dose-response parameters from ex vivo drug testing screens. DSS showed an ability to predict active compounds against malignant cells on various cancer cell models [76] . In a further method that evolved from DSS, Szwajda et al. [77] developed the kinase inhibition sensitivity score (KISS) that maps kinase inhibitor sensitivity and selectivity profiles, and ranks the individual kinases according to the probability of them being essential for the growth of a cancer cell population. The authors found that KISS-based clustering was in agreement with previously defined patient subtypes.
Other mathematical models have been developed to predict the effect of drug combinations. The target inhibition inference using maximisation and minimisation averaging (TIMMA) model deciphers the effects of kinase-targeting compound combinations using available functional data of high-throughput compound sensitivity screens and drug target-binding assays [78] . Alternatively, Gujral et al., [79] focussed on understanding the polypharmacology of a smaller set of 32 kinase inhibitors tested in six cell lines to pinpoint cell type-specific kinases that regulate cell migration. Overall, several approaches using computational tools have been taken to deconvolute the response of cancer cells to kinase inhibitors and to identify kinase targets that regulate the biology of cancer cells and these complement high-throughput approaches that systematically screen for combinatorial effects [80] [81] [82] [83] .
Methodologies for inferring kinase pathway activity
Traditional methods to measure kinase activity As outlined above, several mechanisms contribute to kinase pathway activity, and therefore kinase gene expression does not always correlate with their activity (as illustrated in Fig. 2A , [68] ). Therefore, direct measurements of kinase enzymatic activities may represent the most direct and relevant way of identifying regulatory kinases in signalling networks (Fig. 2B) .
Traditionally kinase activity has been measured by biochemical assays that involve isolation of kinases by immunoprecipitation, followed by in vitro enzymatic assays using 32 P radiolabelled ATP and suitable peptide substrates of the kinase being assayed. Kinase specificity and activity could be determined by quantifying the levels of radioactivity on the peptide substrates [84] . More recently these assays have been done using mass spectrometry (MS) as the readout without the need to immunoprecipitate the kinase of interests [69, 70, 85] . The caveat of in vitro kinase activity measurements is that they require prior knowledge of the targets that should be considered and they are prone to artefacts, as kinase activity is regulated in vivo by protein and substrate localisation, by their interactions with other molecules and by the action of phosphatases that counteract kinase activity.
Chemical biology methods
Chemical biology methods to measure kinase activation rely on the assumption that only active kinases may bind to either ATP [86] or kinase inhibitors immobilised on beads (e.g. kinobeads [87] and multiplex kinase inhibitor beads [88] ). Kinase activation could thus be measured in pull-down assays in which the amount of enriched kinase may be proportional to its extent of activation. These approaches are appealing and have been employed to profile the kinome of large number of cancer cell lines [89] and tissue-derived lysates [90] . However, systemic evaluation of these methodologies suggests that the binding of kinases to immobilised ATP or kinase inhibitors is not proportional to the activation status of kinases in all cases [91, 92] .
Kinase activity inference using MS phosphoproteomics
In contrast to in vitro kinase assays, phosphoproteomics methods allow measuring the phosphorylation levels of kinase substrates (i.e. phosphorylation sites) that have been phosphorylated in vivo. By definition, Figure 2A reproduced from ref. [68] . (B) Several molecular factors, in addition to expression, may affect kinase activity. In this example, a protein kinase phosphorylates a substrate which drives pathway activity (e.g. AKT phosphorylation of PRAS40 or TSC1/2). Pathway activity may be influenced by somatic mutations, by upstream signals and by substrate availability. The action of protein phosphatases opposing the reaction may also be influenced by similar molecular events. Quantifying the phosphoprotein product of the kinase/phosphatase activity provides the most direct method of quantifying pathway activity.
the phosphorylation status of protein residues is the balance product of kinases and phosphatases activities and, thus, phosphoproteomics data could in principle be used to infer kinase activities in a global scale (Fig. 2B) . The methodologies for phosphoproteomics have been reviewed recently [93] [94] [95] [96] [97] and therefore these will not be covered here in detail. We will instead review the basic aspects required for the implementation of phosphoproteomics as a tool to infer kinase pathway activity.
Phosphoproteomics is the biotechnological field that aims to comprehensively identify and quantify phosphorylation events on proteins in a global manner. There are two main approaches used to measure phosphorylation; namely, antibody-based and liquid chromatography tandem-mass spectrometry (LC-MS/ MS)-based methodologies. Classical capture-based assays rely on the specificity of antibodies to bind given phosphorylation sites [98] , and variants of these include western blot, ELISA and immunohistochemistry. Multiplex array assays, including reverse phase protein arrays (RPPA) and Luminex, allow highthroughput measurements of numerous analytes. The utility of these methods to profile phosphoproteomics of clinical samples has been reviewed elsewhere [99] . More recently, microwesterns arrays combine western blotting with RPPA to increase scalability -measuring up to 91 phosphosites in one experiment -while reportedly preventing crossreactivity [100] , and a method dubbed DigiWest couples classic western blot with the bead-based Luminex technology, generating digital and comparable phosphorylation signal intensities [101] .
In contrast to immunochemical techniques, which are restricted to the analysis of a predefined set of targets, MS-based phosphoproteomics approaches have the ability to measure thousands of phosphorylated peptides in a given experiment. In essence, these methodologies involve the extraction and digestion of proteins from samples when performing the widely used the bottom-up proteomics workflow, followed by the selective enrichment of phosphopeptides, using for instance immobilised metal oxides such as TiO 2 [102, 103] . Phosphopeptides are subsequently measured by LC-MS/MS (Fig. 3) . Such strategies have proved successful in identifying > 50 000 phosphopeptides in a single study [104] and > 10 000 phosphopeptides may be routinely quantified with state-of-the-art instrumentation.
Peptide identification is commonly done by search engines such as Mascot [105] , Andromeda [106] , Protein Prospector [107] or X!Tandem [108] to name a few, which compare experimental MS/MS-derived peak lists with in silico-generated peak lists for the given experiment. After being identified, phosphopeptides can be quantified using, for example, extracted ion chromatograms (XICs). There are several software tools developed to obtain quantitative information from MS platforms (e.g. [109] [110] [111] ), and readers interested in their characteristics and the challenges still associated with these tools are referred to a recent review [112] . Kinase activity inference from phosphoproteomics data has now become an interconnected set of computational problems, involving the analysis of datasets produced by mass spectrometers, extracting the appropriate information on phosphorylation levels and amino acid location, from which kinase pathways may be quantified and signalling networks reconstructed.
Overall, LC-MS/MS-based phosphoproteomics methods provide high content information, although challenges inherent to the MS technologies (e.g. insufficient coverage of phosphoproteoforms) and the complex nature of biological systems (e.g. intraheterogeneity of cells) may represent difficulties for the global characterisation of signalling in cell populations. These issues hamper the translation of LC-MS/MS phosphoproteomics platforms to biomarker discovery for personalise medicine. A recent review has highlighted the current status and challenges that still remain in LC-MS/MS-based phosphoproteomics [113] .
Computational inference of kinase activity from phosphoproteomics data
Several computational approaches have been developed to infer kinase activities from shotgun phosphoproteomics data and kinase-substrates relationships, which are annotated in curated databases or estimated from in silico from computational tools (Table 2) . A substantial benefit of these approaches is that the large amounts of complex information generated from phosphoproteomics experiments can be integrated into arrays of kinase activities that are more straightforward to interpret than long lists of phosphorylation sites.
A method to derive values of kinase activity from phosphoproteomic data named kinase-substrate enrichment analysis (KSEA) uses a parametric Z-test (or alternatively two sample t-test or the hypergeometric test) to compare the changes of substrates for a given kinase to all phosphorylation values of a given biological entity [114] . Casado et al., who pioneered this approach for the analysis of Ser/Thr kinases, found that KSEA scores of given kinases correlate with the phosphorylation site markers of kinase activities, as measured by immunoblot. They also showed that the approach may be used to derive values of activity for > 60 kinases in single-shot LC-MS/MS label-free experiments. KSEA accurately predicted sensitivity of primary AML cells to kinase targeted inhibitors [114] . In addition to KSEA, other methods to infer kinase activity from phosphoproteomics data have been reported [115] . A systematic evaluation of these various mathematical approaches, which included KSEA [116] , the Kolmogorov-Smirnov test (and its derivative gene set enrichment analysis, GSEA) the Wilcoxon rank test and the multiple linear regression (MLR) model, demonstrated a good performance of GSEA and KSEA, over the other approaches [117] . This study also highlighted that the number of known substrates per kinase and the source of information on kinase-substrate relationships determine prediction outcomes, with the use of in vivo-validated sources producing more accurate results than when the source of relationships is taken from in silico predictions. Interestingly, and despite the different granularity of the annotation resources (see Table 2 ), KSEA-derived ranking of kinase activities of cancer cells has been used to identify samples' most active kinases and thus likely targets for therapeutic intervention suggesting that absolute kinase ranking is an appropriate method to infer kinase inhibitor sensitivity within individual samples [115] .
Besides those algorithms, KAA (from kinase activity analysis) was developed to predict kinase-substrate relations computationally using the human phosphoproteome as background to assess significant phosphorylation enrichment [118] . Although the predictions made by this method (e.g. enhanced activity of pololike kinases during spermatogenesis) were confirmed experimentally, kinase activities predicted computationally are known to generate incorrect assignments [119] . Alternatively, CLUster Evaluation (CLUE) uses a k-means algorithm to cluster phosphosites that have similar temporal phosphorylation kinetics, from which it is possible to calculate enrichment (with a Fisher's exact test) from prior knowledge kinase-substrate annotations [120] . CLUE may therefore be appropriated to analyse temporal kinase activity profiles in cases where comparisons are amenable to analysis by k-means clustering.
Inference of kinase activities from phosphoproteomics (IKAP) is a heuristic machine learning algorithm that estimates the kinase-substrate links modelling the sum of likely contribution of kinase activities and affinities for their targets [121] . This method estimates the strength of kinase-substrate interactions as well as kinase activities at the cost of having to calculate multiple parameters such as protein expression in addition to phosphorylation. More recently, a method named phosphoproteomic dissection using networks (PHOTON) includes anchor proteins to construct signalling networks based on kinasesubstrate interactions [122] . The signalling networks mediated by EGFR and insulin were reconstructed using this method, and the inferred networks showed improved enrichment in meaningful functional categories compared to their phosphorylated counterparts. A comparison of some of the algorithms developed to infer kinase activity is shown in Table 2 .
Overall, although the notion of kinase activity being measured as a function of substrate phosphorylation is straightforward, inferring kinase activity from phosphoproteomics data and network reconstruction is contingent on a priori assumptions [117] (Fig. 4 and Table 2 ). Large-scale in vitro identifications of kinase selectivity and cell type-specific kinase phosphorylation analyses have increased the reliability of methods used to deduce kinase activities [123, 124] . In silico computational predictions have enlarged information about kinase-substrate relationships, but hypotheses derived from those predictions should be evaluated experimentally [125] . Phosphopeptide arrays may also be used to define phosphorylation motifs [126] , which may then be layered onto MS phosphoproteomics data to further refine kinase activity measurements [114] . Finally, exploring biologically meaningful signalling events by training logic models may contribute to uncover likely networks of kinase-substrate regulatory connections [127] .
Integration of different types of molecular data
The ultimate goal of cancer systems biology is to understand cancer by integrating information on all cell molecular components, including genes, proteins and networks [128] . To this end, bioinformatics algorithms have been developed to integrate multiple datasets to better understand the complexity of cancer molecular biology (Table 2) . One such approach, ReKINect, characterises the functional consequences of exome mutations on specific phosphorylation sites Gene expression, mutation data and phosphoproteomics data https://sysbiowiki.soe.ucsc.edu/tiedie [133] SNVs, single nucleotide variants; CNAs, copy number aberrations; WES, whole exome sequencing.
or on global signalling networks [129] . Using this tool, the developers highlighted that mutations that are considered as neither activating nor inactivating can yet be functional because of their effects on signalling networks. In a separate study, integration of phosphoproteomics data in proteogenomics analysis of breast cancer cells identified G-protein coupled receptor (GPCRs) and PI3K activity signatures that were not detected by previous risk predictors based on mRNA expression level [130] . An additional example of the high-throughput data integration trend in curated databases is the incorporation in PhosphoSitePlus of the dataset PTMVar, which maps nonsynonymous mutations onto the sequence space for phosphorylation and other post-translational modifications [131] . Integrative approaches may be able to translate the acquired knowledge to clinical management of cancer, in order to detect vulnerabilities of cancer cells that may be used to prioritise treatments in a personalised manner. Ryall et al. [132] gathered publicly available gene expression data as well as kinase inhibition and drug sensitivity data and applied the kinase addiction ranker (KAR) on 21 lung cell lines and samples of 151 leukaemia patients tested with 66 kinase inhibitors. However, the validation of the predictive capacity of kinase dependency of the KAR algorithm was only probed in one epithelial lung cell line. Another individualised systems medicine (ISM) approach integrated the ex vivo chemosensitivity of 28 bone marrow blast samples of AML patients to 187 drugs after 72 h of treatment with the molecular profiling of patients who could then be grouped by hierarchical clustering based on mutational profiles and drug-responses. Of note, this study emphasised the need for personalised drug treatment and showed a lack of correlation between genomic data and drug response [32] . In addition, the ISM approach allowed the exploration of acquired resistance mechanisms to targeted inhibitors of cancer cells of treated patients performing phenotypic drug sensitivity and resistance testing (DSRT) [32] . A recent study used an algorithm named tied diffusion through interacting events (TieDIE) [133] to integrate Readers interested in guidelines that assist selecting the most appropriated curated signalling resources are referred to [141] .
phosphoproteomics data of patients suffering metastasis castration resistant prostate cancer (mCRPC) with genomics and transcriptomics data to develop patientspecific networks and uncovered enrichment of proteins involved in the PI3K/AKT/mTOR and MAPK, cell cycle and nuclear receptor pathways after inclusion of the phosphoproteomics data [115] . Taken together, several methodologies have been developed to organise the information obtained by different high-throughput biotechnological techniques; ultimately, the goal of these approaches is to select effective therapy for personalised medicine by profiling individualised molecular signatures.
Although the translational application of these integrative approaches is appealing, it is important to note that the predictive nature of algorithms if often tested in ex vivo model systems. However, the responses of cancer cells to a given treatment can be altered by the ex vivo environment [134] . To address this limitation, some studies have explored ways to recreate the heterogeneous tumour microenvironment ex vivo [135] ; for example, Majunder et al. [136] designed an ex vivo platform that resembles the tumour microenvironment and measured various tumour responses to demonstrate 87.27% accuracy in predicting responses in 55 patients of head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) to treatment with 5-fluorouracil (5-FU).
Empirical comparison of the methods used to integrate different complex types of data is required to assess accuracy, as well as, in vivo confirmation of the predicted responses to kinase targeted inhibitor. Additionally the heterogeneity observed within cancer cell populations and across patients means predicting responses to anticancer treatment is not a trivial task, and approaches to account for tumour heterogeneity whist integrating complex cancer molecular datasets are yet to be reported.
Conclusions
Functional assays based on RNAi and drug screenings have complemented gene sequencing efforts for the identification of kinase targets in different cancer types. These functional screenings, however, are laborious and unsuitable for the identification of patient-specific targets in clinical settings, although drug testing in patient-derived xenografts are promising for screening a reduced number of compounds [32, 137] . Alternative approaches involve measuring the molecular make up of cancer cells from an omics perspective. While NGS and RNA-Seq provide robust platforms to profile genetic mutations and gene expression, inferring the activity of protein kinases that drive intracellular signal transduction is arguably better achieved using phosphoproteomics approaches. The computational problem of inferring signalling pathway activity from these data is being solved with advances in computational biology and with the development of databases of validated kinase-substrate relationships. More work is required to annotate the phosphoproteome with the kinases acting upstream of each phosphorylation site because at present only a small proportion of sites detected in standard phosphoproteomics experiments are annotated with the kinase(s) that catalyse their phosphorylation. Additionally, future models may need to consider the impact of other PTMs (such as ADP-ribosylation and O-GlcNacylation), which by modifying serine residues may compete for phosphorylation and thus have an effect on the phosphoproteome [138, 139] . Further developments will come from a new generation of algorithms to integrate various types of biological data. Nevertheless, although computational approaches for integrating different forms of omics data are still on their infancy [140] , these are already starting to provide unprecedented insights into cancer biology and with further refinements these technologies may in the future also be translated into clinical applications. Approaches for measuring signalling plasticity in the
